Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday

Olema Pharmaceuticals (NASDAQ:OLMA) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ OLMA opened at $4.60 on Monday. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $16.62. The firm has a market capitalization of $314.46 million, a PE ratio of -2.10 and a beta of 2.03. The stock’s 50-day simple moving average is $4.27 and its 200-day simple moving average is $6.29.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Monday, April 28th. JPMorgan Chase & Co. dropped their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, March 28th. Finally, Oppenheimer restated an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.